Literature DB >> 2955055

Isotretinoin produces significant inhibition of monocyte and neutrophil chemotaxis in vivo in patients with cystic acne.

D A Norris, R Osborn, W Robinson, M G Tonnesen.   

Abstract

The effect of oral isotretinoin (13-cis-retinoic acid) on in vivo chemotactic responses was studied longitudinally in 7 patients with cystic acne. As measured in a microchamber chemotaxis assay, both monocyte and neutrophil chemotaxis were inhibited 98% (p less than 0.001) during isotretinoin treatment. In vivo chemotactic responses returned to normal within 2 months of cessation of treatment. Biopsies of skin chamber sites from patients on isotretinoin showed no significant dermal or epidermal leukocytic accumulation in response to autologous zymosan-activated serum, whereas chambers from controls showed extensive neutrophilic infiltrates even in the epidermis. In contrast, in vitro chemotactic responses of neutrophils and monocytes from patients on isotretinoin were not diminished. Sera and plasma from patients on isotretinoin contained no inhibitors of chemotaxis, and activated sera from these patients were excellent attractants for normal monocytes. We postulate that isotretinoin produces significant anti-inflammatory effects by inhibition of monocyte and neutrophil chemotaxis across intact biologic barriers in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955055     DOI: 10.1111/1523-1747.ep12580370

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

1.  [Rosacea. Systemic therapy with retinoids].

Authors:  A Thielitz; H Gollnick
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

2.  [IgA pemphigus of the subcorneal pustular dermatosis type. Successful therapy with a combination of dapsone and acitretin].

Authors:  B Monshi; L Richter; T Hashimoto; E Groiß; N Haensch; K Rappersberger
Journal:  Hautarzt       Date:  2012-06       Impact factor: 0.751

Review 3.  Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.

Authors:  F G Larsen; F Nielsen-Kudsk; P Jakobsen; K Weismann; K Kragballe
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

4.  A Novel Inflammatory Marker in the Follow-up of Moderate-to-Severe Acne Vulgaris Administered Isotretinoin: Systemic Immune-Inflammation Index (SII).

Authors:  Çağri Turan; Nurcan Metin
Journal:  Curr Health Sci J       Date:  2022-03-31

5.  Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.

Authors:  Raed O Alhusayen; David N Juurlink; Muhammad M Mamdani; Richard L Morrow; Neil H Shear; Colin R Dormuth
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

6.  The effect of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin.

Authors:  G Wozel; A Chang; M Zultak; B M Czarnetzki; R Happle; J Barth; P C van de Kerkhof
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

7.  Clarifying the Purported Association between Isotretinoin and Inflammatory Bowel Disease.

Authors:  Steven S Coughlin
Journal:  J Environ Health Sci       Date:  2015       Impact factor: 2.130

8.  Effects of all-trans retinoic acid on neutrophil-mediated endothelial cell injury in vitro and immune complex injury in rats.

Authors:  J Varani; J Jones; M Dame; C Sulavik; D F Gibbs; K J Johnson
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

Review 9.  Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.

Authors:  Rami A Al-Horani; Srabani Kar; Kholoud F Aliter
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.